ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Ashvattha Therapeutics to Present Data on Novel Nanomedicine Radiotracers at SNMMI Annual Meeting

REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced it will present data on two novel nanomedicine radiotracers at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21 – 24, 2025 in New Orleans, LA.

The data will demonstrate the ability to tune Ashvattha's hydroxyl dendrimer platform to achieve selective uptake in neuroinflammation in humans and in tumor-associated macrophages in cancer animal models.

The company will present findings on two novel nanomedicine radiotracers: flurimedrimer, which selectively targets activated microglia in the human brain to support its neurology pipeline, and a second radiotracer designed to selectively target tumor-associated macrophages, potentially advancing precision imaging in oncology.

SNMMI:

  • Poster Title: Flurimedrimer, a Novel Nanomedicine Radiotracer, Selectively Targeting Activated Microglia in Human Brain
  • Presentation Date/Time: Sunday, June 22, 2025; 6:30-7:00pm CDT
  • Session Type: Molecular Targeting Probes POPs
  • Presenter: Farshad Moradi, MD, Stanford University

  • Poster Title: A Novel Nanomedicine Radiotracer, Selectively Targeting Tumor Associated Macrophages
  • Presentation Date/Time: Monday, June 23, 2025; 10:30 AM-11:15am CDT
  • Session Type: Poster Session
  • Presenter: Jeff Cleland, PhD, CEO, Ashvattha Therapeutics


About Ashvattha Therapeutics 

Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, oncology, and inflammation. Ashvattha Therapeutics was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and incubated by Natural Capital. For more information, visit: www.avttx.com

Media
ICR Healthcare
AshvatthaPR@icrhealthcare.com

Investor Relations
Aman Patel, CFA & Adanna G. Alexander, PhD
AshvatthaIR@icrhealthcare.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.